Last reviewed · How we verify
NCT06888765
Effects of Differences in Body Composition on Retina and Choroid
trial testing Optical Coherence Tomography (OCT) and Body Composition Analysis in Obesity in 261 participants. Completed in 1 January 2025.
1 October 2024
Quick facts
| Lead sponsor | Bayram Meydan |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 261 |
| Start date | 1 July 2024 |
| Primary completion | 1 October 2024 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Optical Coherence Tomography (OCT) and Body Composition Analysis
Conditions studied
- Obesity — all drugs for Obesity →
- Obesity, Morbid — all drugs for Obesity, Morbid →
- Body Composition — all drugs for Body Composition →
Sponsor
Bayram Meydan
Who can join
Adults 18 to 65, any sex, with Obesity or Obesity, Morbid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to examine the effects of body composition differences on retinal and choroidal structures. The study aims to investigate how variations in fat distribution and body composition parameters influence ocular microvascular structures. The main questions it aims to answer are: * How do differences in body composition (BMI, waist circumference, bioelectrical impedance parameters) affect retinal and choroidal microvascular structures? * Are there significant structural changes in the retina and choroid among individuals with different body composition profiles? Participants will: * Be classified into five groups based on their Body Mass Index (BMI) (underweight, normal weight, overweight, obese, and severely/morbidly obese). * Undergo detailed body composition analysis using bioelectrical impedance analysis (BIA) to assess fat mass, muscle mass, visceral fat index, and metabolic age. * Receive comprehensive ophthalmologic evaluations, including Optical Coherence Tomography (OCT) and Optical Coherence Tomography Angiography (OCTA), to measure retinal thickness, choroidal thickness, and microvascular parameters. * OCTA images will be analyzed using the OCTAVA software to compute vascular parameters. This study does not involve any new treatments, drugs, or interventional procedures. The findings aim to provide insights into the relationship between body composition and ocular microvascular health, contributing to early detection and prevention strategies for obesity-related ocular complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06888765
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06888765 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bayram Meydan
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06888765.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing